One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity, PubMed.gov, Wissam Ghusn, Alan De la Rosa, Daniel Sacoto, Lizeth Cifuentes, Alejandro Campos, Fauzi Feris, Maria Daniela Hurtado, Andres Acosta
2024 [citato 30 giugno 2024]
Alpha Lipoic Acid & AHA: Promote cell renewal and exfoliation, revealing fresher, younger-looking skin